An assessment of the efficacy and safety of biotherapy infliximab in the treatment of ulcerative colitis

Abstract

Ulcerative colitis (UC) is a chronic inflammatory bowel disease with increasing global prevalence and considerable impact on patients’ quality of life. Biological therapies, particularly tumor necrosis factor-alpha (TNF-α) inhibitors such as infliximab, have demonstrated effectiveness in managing moderate to severe UC. This study aimed to evaluate the therapeutic efficacy and safety of infliximab in Libyan UC patients. A structured questionnaire was administered to 100 patients attending Tripoli University Hospital in August 2024. Collected data included demographic information, treatment regimens, symptom improvement, side effects, and psychosocial support. Results revealed that younger patients (15–26 years) constituted the majority of cases and showed the highest rates of symptom improvement (≥70%). Gastrointestinal side effects were minimal across all groups, though older patients were more likely to report complications. A significant need for psychological support was observed across all age groups, underscoring the importance of integrated mental health care in UC management. Infliximab was generally well-tolerated, with favorable outcomes in disease control and quality of life. Future studies are recommended to further investigate long-term safety, optimize treatment strategies, and explore adjunctive psychosocial interventions.